A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG: PF-05221304 Monotherapy
DRUG: PF-06865571 Monotherapy
DRUG: Placebo
DRUG: PF-05221304 and PF-06865571 Combination

Sponsor

Pfizer